Yes, targeting MDM2 is a promising strategy for cancer therapy. Inhibitors that block the interaction between MDM2 and p53 are being developed to reactivate p53 activity in tumors where MDM2 is overexpressed. This approach aims to restore the normal function of p53, promoting the elimination of cancerous cells through cell cycle arrest or apoptosis. Such therapeutic interventions highlight the intersection of toxicology and pharmacology.
